

Pfizer-BioNTech

# COMIRNATY®

mRNA COVID-19 vaccine  
Omicron KP.2 Formulation

≥ 12 years

**DIN 02541823**

**Dark Grey Cap, Light Grey Label**



**SUPPLIED:**

multidose vial;  
**30 mcg/0.3 mL**



**PREPARATION:**

ready-to-use;  
**DO NOT DILUTE**



**ADMINISTRATION:**

**IM injection**



**APPROPRIATE USE:**

- **12 years & older**
- Eligibility, intervals, and additional considerations: see QR code



**BEYOND-USE EXPIRY DATE/TIME:**

- **Check date on carton** (expiry date) and **extensions** (in VDTS, Panorama, or CQE)
- **Unpunctured:**
  - 2°C to 8°C: use vaccine within 10 weeks
  - >8°C to 25°C: puncture vial within 12 hours\*

\* Vials can be returned to fridge; however, any time kept above 8°C needs to be tracked and cannot exceed 12 hours prior to first puncture.
- **Punctured:** 2°C to 25°C: use vaccine within 12 hours\* of first puncture
- \* Does not include time at room temperature prior to first puncture.



**HANDLING:**

- Before use, invert vial gently 10 times to mix; **DO NOT SHAKE**
- Can be handled in room light conditions



**APPEARANCE:**

- Prior to inversion, may contain white to off-white opaque amorphous particles
- After inversion, should appear as white to off-white suspension
- **NO particles/discolouration**



**DOSE:**

**0.3 mL** (30 mcg)

Number of doses and intervals vary based on previous vaccination and immune status. See QR code for details.

**REFERENCE:**

- Comirnaty Product Monograph. BioNTech Manufacturing GmbH. Distributed by Pfizer Canada ULC; 2024. Accessed October 3, 2024. <https://covid-vaccine.canada.ca/info/pdf/comirnaty-kp2-pm-en.pdf>

*Financial contribution:*



Public Health  
Agency of Canada

Agence de la santé  
publique du Canada